InMed Pharmaceuticals Inc (INM)

[OTCRIDER]

InMed Pharmaceuticals is a clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

InMed is utilizing its proprietary "Intelligent Cannabinoid Drug Design Platform" to identify new bioactive compounds within the cannabis plant that interact with certain gene responsible for specific diseases.

Our Proprietary Platform Technology, Product pipeline and accelerated drug discovery/development pathway are the fundamental value drivers of the Company.



InMed's botanical research team has begun to develop the individual strains & clones that will produce the raw material bases for future pharmaceutical research.


Pipeline

CTI-085

Is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma. InMed has identified our lead composition (CTI 085) through 12 months of discovery and preclinical studies that showed efficacy in lowering intraocular pressure (IOP) in animal models. Cannabinoids have IOP lowering effects, thus, they have therapeutic potential in the treatment of glaucoma. Our objective for this therapy was to develop a safer; cannabis based topical anti-glaucoma formulation without systemic side effects.

CTI-091

Is a proprietary mixture of cannabinoids and non-cannabis based active ingredients designed for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation. We are currently developing an innovative new delivery system to enhance retention and absorption of the key active ingredients around the target site to relieve joint pain and swelling.



Press Releases


October 23, 2014 InMed Commences Development of Proprietary Drug Delivery System
October 21, 2014 Cannabis Technologies Inc. Now Trading as InMed Pharmaceuticals Inc.
October 16, 2014 Cannabis Technologies Inc. Changes Name to InMed Pharmaceuticals Inc.
September 09, 2014 Cannabis Technologies Appoints Peter Huang as Senior Bioinformatician
August 18, 2014 Cannabis Technologies Announces Second Therapy-CTI 091
July 16, 2014 Cannabis Technologies Announces Momentum PR
June 24, 2014 Cannabis Technologies Announces Glaucoma Therapy Entering into Phase 1 Clinical Trials
June 10, 2014 Cannabis Technologies Appoints Dr. Tarek S. Mansour, Ph.D. to Scientific Advisory Board
June 04, 2014 Cannabis Technologies Commences Trading on OTCQB
May 21, 2014 Cannabis Technologies Commences trading on CSE



July 18, 2014
2014 CTV Morning Live
Publisher: CTV News
http://www.cannabis-tech.com/s/media.asp?ReportID=665288&_Type=Media&_Title=2014-CTV-Morning-Live